Tarsus Pharmaceuticals (NASDAQ:TARS) versus Windtree Therapeutics (NASDAQ:WINT) Financial Analysis

Tarsus Pharmaceuticals (NASDAQ:TARSGet Free Report) and Windtree Therapeutics (NASDAQ:WINTGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Tarsus Pharmaceuticals and Windtree Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tarsus Pharmaceuticals 0 1 7 0 2.88
Windtree Therapeutics 0 1 0 0 2.00

Tarsus Pharmaceuticals currently has a consensus target price of $50.38, indicating a potential upside of 56.01%. Given Tarsus Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Tarsus Pharmaceuticals is more favorable than Windtree Therapeutics.

Valuation and Earnings

This table compares Tarsus Pharmaceuticals and Windtree Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tarsus Pharmaceuticals $17.45 million 69.91 -$135.89 million ($4.77) -6.77
Windtree Therapeutics N/A N/A -$20.29 million ($143.89) -0.02

Windtree Therapeutics has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tarsus Pharmaceuticals and Windtree Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tarsus Pharmaceuticals N/A -71.12% -55.30%
Windtree Therapeutics N/A -62.91% -17.14%

Risk and Volatility

Tarsus Pharmaceuticals has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Institutional and Insider Ownership

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Tarsus Pharmaceuticals beats Windtree Therapeutics on 8 of the 12 factors compared between the two stocks.

About Tarsus Pharmaceuticals

(Get Free Report)

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

About Windtree Therapeutics

(Get Free Report)

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitorfor the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has collaboration with Chang Gung University; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.